CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent “Want Money Got Money” podcast. Hosted by author, founder, speaker and CEO Sam Kamani, the podcast series shares stories, secrets and skills of the world’s most brilliant and interesting start-up founders and investors. During the podcast, Climaco talked about recent research conducted by CNSP founder Dr. Waldemar Priebe that studies the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. In addition, Climaco discussed CNS Pharmaceuticals’ lead drug candidate, Berubicin. The drug is being proposed as a treatment for GBM. A Phase I clinical trial evaluating the drug has been completed, and CNS has applied to begin a Phase II clinical trial. Climaco noted the slow progress in treatments for glioblastoma and observed that Berubicin has potential to significantly impact the prognosis for GBM patients worldwide. “Berubicin looks and acts and kills cancer cells just like every other anthracycline, but the secret sauce is that it gets into the brain,” Climaco said. “What Dr. Priebe did was address a very defined and, in the grand scheme, a small innovation, but it’s an absolutely critical innovation for the application of this type of drug to this type of cancer. We are laser-focused on designing the best possible study for this drug in the best environment with the best patients. With our partner in Europe, we’re expecting to test almost 300 patients over the next couple of years.”
To hear the full podcast, visit https://ibn.fm/6JvEN
To view the full press release, visit https://ibn.fm/y6qJP
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
